Drug Profile
Cefuroxime pulsatile - Advancis
Alternative Names: Cefuroxime PULSYS™ - Advancis; Pulsatile cefuroxime - AdvancisLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Advancis Pharmaceutical
- Class Antibacterials; Cephalosporins
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 26 May 2006 No development reported - Preclinical for Bacterial infections in USA (PO)
- 31 Dec 2003 Preclinical trials in Bacterial infections in USA (PO)